Brief: Arcutis Biotherapeutics Q4 basic EPS USD -0.72
27/02/2024 10:53
Feb 27 (Reuters) - Arcutis Biotherapeutics Q4 basic EPS USD -0.72 vs. IBES estimate USD -0.78. * Q4 net income USD -66.284 million * Q4 operating income USD -61.169 million vs. IBES estimate USD -68.7 million * Q4 product revenue USD 13.526 million * Q4 operating expenses USD 74.695 million
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Canada Przoryve Cream 0.05% Receives Health Canada Approval For Atopic Dermatitis
Arcutis Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlook
Arcutis Biotherapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview
Brief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4